Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merus B.V.
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Stanford University
Medical College of Wisconsin
National Cancer Institute (NCI)
Ensem Therapeutics
AstraZeneca
Seagen Inc.
University of Colorado, Denver
Genmab
Seagen Inc.
Fulgent Pharma LLC.
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School
Johnson & Johnson Enterprise Innovation Inc.
University of Erlangen-Nürnberg Medical School
Exelixis
Mayo Clinic
University of California, Davis
University of Kentucky
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Kivu Bioscience Inc.
Vanderbilt-Ingram Cancer Center
EpiBiologics
M.D. Anderson Cancer Center
Fox Chase Cancer Center
Eastern Cooperative Oncology Group
AstraZeneca
University Health Network, Toronto
University Health Network, Toronto
Case Comprehensive Cancer Center
Bicara Therapeutics
STORM Therapeutics LTD
Emory University
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tubulis GmbH